Diabetic nephropathy is a progressive kidney disease associated with diabetes mellitus – type 1 and type 2 – affecting kidney glomeruli, arterioles, tubules and the interstitial. Clinical features include macro albuminuria and a reduction in glomerular filtration rate that may lead to end-stage renal disease, requiring dialysis or kidney transplantation. Treatment options and decisions are often based on the results of clinical trials. We have evaluated the public availability of results from completed, registered phase III clinical trials on diabetic nephropathy and current treatment options. This was a cross-sectional analysis in which Strengthening the Reporting of Observational studies in Epidemiology criteria were applied for design and analysis. In June 2017, 34 completed phase III clinical trials on diabetic nephropathy in the Clinical Trials. registry were identified and matched to publications in the ClinicalTrials.gov registry and to those in the PubMed and Google Scholar databases. If no publication was identified, the principal investigator was contacted. The ratio of published and non-published studies was calculated. Various parameters, including study design, drugs, and comparators provided, were analysed. Citations are important for a journal to get impact factor. Impact factor is a measure reflecting the average number of citations to recent articles published in the journal. The impact of the journal is influenced by impact factor, the journals with high impact factor are considered more important than those with lower ones. This information can be published in our peer reviewed journal with impact factors and are calculated using citations not only from research articles but also review articles (which tend to receive more citations), editorials, letters, meeting abstracts, short communications, and case reports.